Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis.

1 , 2 Due to the 2019 global burden of disease (GBD) report, prevalence of MS in 2016 was estimated to be 2.22 million, which represented an increasing trend of 10.4% since 1990. 2 MS usually starts in most productive years of adult life (15-45 years) and mostly in women. 3 , 4 This disorder is categorized into four types: relapsing-remitting MS (RRMS), primary progressive MS (PPMS), secondary progressive MS (SPMS), and progressive-relapsing MS (PRMS).

also in 63,971 other papers